Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 75/100

Failure Rate

25.0%

1 terminated/withdrawn out of 4 trials

Success Rate

66.7%

-19.8% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 2 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 2
1(100.0%)
1Total
Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT04366921Unknown

European/Euro-ELSO Survey on Adult and Neonatal/ Pediatric COVID-19 Patients in ECMO

Role: collaborator

NCT01631409Withdrawn

Estimation of the Long Term Effectiveness of Routine Use of Cardiac Shock Wave Therapy

Role: lead

NCT00901381Phase 2Completed

Granulocyte-colony Stimulating Factor for Stem Cells Therapy for Acute Ischemic Stroke

Role: collaborator

NCT00893633Completed

Critical Illness Neuromuscular Abnormalities in Neurocritical Care Patients

Role: collaborator

All 4 trials loaded